Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LUTETIUM LU-177 vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LUTETIUM LU-177 vs LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN: Safety Overview

Metric LUTETIUM LU-177 LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Total FAERS Reports 114 10,716
Deaths Reported 13 1,461
Death Rate 11.4% 13.6%
Hospitalizations 32 545
Average Patient Age 66.4 yrs 72.9 yrs
% Female Patients 27.6% 0.7%
FDA Approval Date N/A Mar 23, 2022
Manufacturer N/A Novartis Pharmaceuticals Corporation
Route N/A INTRAVENOUS
Marketing Status N/A Prescription